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  24 
SUMMARY 25 
Leishmaniasis is one of the world’s most neglected diseases, and it has a worldwide 26 
prevalence of 12 million. There are no effective human vaccines for its prevention, and 27 
treatment is hampered by outdated drugs. Therefore, research aiming at the 28 
development of new therapeutic tools to fight Leishmaniasis remains a crucial goal 29 
today. With this purpose in mind, we present twenty arylaminoketone derivatives with a 30 
very interesting in vitro and in vivo efficacy against Trypanosoma cruzi that have now 31 
been studied against promastigote and amastigote forms of L. infantum, L. donovani and 32 
L. braziliensis strains. Six out of the twenty Mannich base-type derivatives showed 33 
Selectivity Index between 39 and 2337 times higher in the amastigote form than the 34 
reference drug glucantime. These six derivatives affected the parasite infectivity rates; 35 
the result was lower parasite infectivity rates than glucantime tested at a IC25 dose. In 36 
addition, these derivatives were substantially more active against the three Leishmania 37 
species tested than glucantime. The mechanism of action of these compounds has been 38 
studied, showing a greater alteration in glucose catabolism and leading to greater levels 39 
of Fe-SOD (iron superoxide dismutase) inhibition. These molecules could be potential 40 
candidates for Leishmaniasis chemotherapy. 41 
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  46 
KEY FINDINGS 47 
1. Arylaminoketone Mannich base-type derivatives have been studied as potential 48 
candidates for Leishmania therapy. 49 
2. The tested compounds showed less cytotoxicity in macrophages than glucantime 50 
3. Compounds showed higher intracellular activity than glucantime in the promastigote 51 
and amastigote forms of three Leishmania spp. 52 
4. The lead compounds used against three Leishmania spp. affected the parasite 53 
infectivity rates; the result was lower parasite infectivity rates than glucantime tested 54 
at a IC25 dose. 55 
5. Compounds produced a greater alteration in glucose catabolism and Fe-SOD 56 
inhibition; this could be related to mitochondrial malfunction. 57 
  58 
INTRODUCTION 59 
Leishmaniasis caused by the intracellular protozoan Leishmania is one of the world’s 60 
most neglected diseases. (WHO, 2016). 61 
Although the immunology, biology and genetics of the parasites causing these diseases 62 
have been studied extensively, there are no effective human vaccines for their 63 
prevention, and treatment of kinetoplastid infections is hampered by outdated drugs. 64 
(Uliana et al. 2017). The use of these drugs has been limited due to their elevated cost, 65 
side effects, variable degree of efficacy, route of administration, long treatment duration 66 
and the emergence of drug-resistant strains. Therefore, research aiming at the 67 
development of new therapeutic tools to fight Leishmaniasis remains a crucial goal 68 
today (Menezes et al. 2015). 69 
The design of new potential drugs for Leishmania treatment claims to understand the 70 
essential metabolic biochemical pathways and crucial parasite- specific enzymes. In this 71 
context, enzymes that can help to avoid the damage caused by oxidative stress have 72 
emerged as interesting targets (Coimbra et al. 2016; Singh et al. 2016). The most 73 
interesting ones are those that present biochemical and structural differences with their 74 
human counterparts (Menna-Barreto and de Castro, 2014; Hunter et al. 2003; Piacenza 75 
et al. 2006). It has been shown that superoxide dismutase (Fe-SOD) enzyme plays an 76 
important role in the defense of trypanosomatids against oxidative agents. It is exclusive 77 
to the parasite, and parasitic protozoan survival is closely related to the ability of this 78 
enzyme to evade toxic radical damage originated by their host. (Sanz et al. 2008; 79 
Sánchez-Moreno et al. 2011; Turrens 2004; Bodyl and Mackiewicz, 2008).  80 
From a chemical point of view, thiophene entity is a promising scaffold in medicinal 81 
chemistry due to its broad spectrum as an anti-inflammatory, analgesic or antibacterial 82 
(Arun et al. 2010; Issa et al. 2009; Puterová and Krutosilová 2010). Moreover, the 83 
potential of thiophene derivatives as leishmanicidal agents only or in combination with 84 
other moieties has also been reported (Félix et al. 2016), and the leishmanicidal 85 
properties for a range of benzodioxole derivatives have also been described (Fernandes 86 
et al. 2015; Parise-Filho 2012). Naphthalene derivatives have already been described for 87 
their antileishmanial activity (Manzano et al. 2016; Mori-Yasumoto et al. 2012). The 88 
interest in Mannich base-type derivatives as drugs or drug candidates is well known and 89 
their antitrypanosomal action has been reported (Lee et al. 2005; Wenzel et al. 2009; 90 
Mahal et al. 2017). Moreover Mannich reaction is an important tool for C-C bond 91 
formation in organic chemistry, widely used for the preparation of β-aminoketones used 92 
as antiparasitic agents. So, taking into account the potential of these scaffolds we 93 
decided to explore the antitrypanosomal capacity of a new family of Mannich base 94 
derivatives.  95 
Recently, our research group has described the in vitro and in vivo anti T. cruzi activity 96 
of 20 arylaminoketone Mannich base-type compounds obtained by condensation of the 97 
corresponding arylamines and different aromatic rings with interest in medicinal 98 
chemistry including thiophene, benzothiophene, benzodioxole and naphthalene  (see 99 
supplementary information) (Moreno-Viguri et al. 2016). This family of compounds has 100 
shown promising activity in the infective forms of the parasites, and no genotoxicity or 101 
mutagenicity was observed in the primary screening. The mechanism of action of these 102 
compounds has been studied at metabolic levels by 1H NMR (Nuclear Magnetic 103 
Resonance), and the study has been completed by testing their activity against Fe-SOD. 104 
These molecules could be potential candidates for Leishmania therapy (Turrens et al. 105 
2004; Sanchez-Moreno et al. 2015) because they show selectivity over FeSOD. 106 
Therefore, we decided to test these molecules against promastigote and amastigote 107 
forms of L. infantum, L. donovani and L. braziliensis strains.  108 
MATERIALS AND METHODS 109 
Chemistry 110 
The synthesis of the arylaminoketone Mannich base compounds (1-20) was previously 111 
described (Moreno-Viguri et al 2016). The desired compounds were prepared by 112 
condensation of the corresponding methylketone with the appropriate arylamine via 113 
Mannich reaction in acidic medium and using 1,3-dioxolane as the solvent and the 114 
formaldehyde source. Purification of the compounds was performed in all cases using 115 
Flash column chromatography eluting in gradient with CH2Cl2/methanol. Spectroscopic 116 
data were the same as those described in reference (Moreno-Viguri et al. 2016) and the 117 
adequate purity of the compounds was confirmed by the analytical data. 118 
Parasite strain and culture 119 
Promastigote forms of L. infantum (MCAN/ES/2001/UCM-10), L. braziliensis 120 
(MHOM/BR/1975/M2904) and L. donovani (LCR-L 133 LRC, Jerusalem (Israel) were 121 
cultured in vitro in medium trypanosomes liquid (MTL) supplemented with 10% 122 
inactive fetal calf serum (FCS) and kept in an air atmosphere at 28ºC in Roux flasks 123 
(Corning, USA) with a surface area of 75 cm2, following the methodology described by 124 
González, P. et al. 2005. 125 
In vitro activity assays 126 
The tested compounds were first dissolved in dimethyl sulfoxide (DMSO, Panreac, 127 
Barcelona, Spain) at a final concentration of 0.1% and then assayed for toxicity and 128 
inhibitory effects on parasite and mammalian cell growth as previously described by 129 
González et al. 2005. 130 
Cell culture and cytotoxicity tests 131 
The macrophage line J774.2 [European collection of cell cultures (ECACC) number 132 
91051511] was used for the cytotoxicity test. The macrophages were cultured and the 133 
cytotoxicity testing was performed by flow cytometry analysis according to a method 134 
previously described (Kirkinezos and Moraes, 2001) 135 
Promastigote and amastigote assay 136 
The compounds were dissolved in the culture medium to give final concentrations of 137 
100, 50, 25, 10 and 1 µM. The effects of each compound against the promastigote forms 138 
at the different concentrations were tested according to the methodology described by 139 
González et al. 2005. The inhibition effect was expressed as the IC50 value, i.e. the 140 
concentration required to result in 50% inhibition, calculated by linear regression 141 
analysis. 142 
In the case of amastigote forms, J774.2 macrophage cells were cultured and seeded at a 143 
density of 1x104 cells per well in 24-well microplates (Nunc) with rounded coverslips 144 
on the bottom and cultured for 2 days, according to the method described by Sánchez-145 
Moreno et al. 2012. 146 
Infectivity assay 147 
Adherent macrophage cells grown as described above were infected in vitro with 148 
promastigote forms of L. infantum, L. braziliensis and L. donovani at a ratio of 10:1. 149 
The tested compounds (IC25 concentrations) were added immediately after infection, 150 
and incubated for 12 h at 37ºC in 5% CO2 (Gonzalez et al. 2005). Compounds and 151 
nonphagocytosed parasites were removed by washing, and then the infected cultures 152 
were cultured for 10 days in fresh medium. Cultures were washed every 48 h and fresh 153 
culture medium was added. Compound activity was determined on the basis of both the 154 
percentage of infected cells and the number of amastigotes per infected cell in treated 155 
and untreated cultures in methanol-field and Giemsa-stained preparations. The 156 
percentage of infected cells and the mean number of amastigotes per infected cell were 157 
determined by analyzing more than 200 host cells distributed in randomly chosen 158 
microscopic fields. 159 
Metabolite excretion 160 
Cultures of L. infantum, L. braziliensis and L. donovani promastigotes (initial 161 
concentration 5 x 105 cells per mL) received the IC25 dose of each compound (except 162 
for control cultures). The methodology used was described by Fernandez-Becerra et al. 163 
1997. 164 
Superoxide Dismutase (SOD) Inhibition Studies 165 
Promastigotes of Leishmania spp. were grown in tissue-culture flasks and an axenic 166 
medium, as described above, until reaching a population of approximately 1 × 107 167 
parasites/mL. Cells were harvested at the logarithmic growth phase by centrifugation 168 
(1500 ×g for 10 min at room temperature). The pellet of cells was washed twice in MTL 169 
medium without serum, and the cells were counted, distributed into aliquots of 5 × 109 170 
parasites/mL in MTL medium without serum, and llowed to grow for 24 h. 171 
After 24 h, the promastigote culture was centrifuged (1500 ×g for 10 min) and the 172 
supernatant was filtered (Minisart®,Φ 20 μm). The filtered supernatant was subjected to 173 
ice-cold ammonium sulphate precipitation at 35% salt concentration. Following 174 
centrifugation, the resultant supernatant was then treated with 85% ice-cold ammonium 175 
sulphate and the second precipitate was collected. The resulting precipitate was finally 176 
dissolved in 2.5 mL of distilled water and desalted by chromatography in a Sephadex G-177 
25 column (GE Healthcare Life Sciences®, PD 10 column), previously equilibrated 178 
with 25 mL of distilled water, bringing it to a final volume of 3.5 mL (Fraction P85e). 179 
The protein content was quantified using the Sigma Bradford test, which uses bovine 180 
serum albumin (BSA) as a standard (Bradford, 1976). Iron and copper-zinc superoxide 181 
dismutases activities were determined using a previously described method (Beyer and 182 
Fridovich, 1987) that measures the reduction in nitroblue tetrazolium (NBT) by 183 
superoxide ions. According to the protocol, 845 μL of stock solution [3 mL of L-184 
methionine (300 mg, 10 mL−l), 2 mL of NBT (1.41 mg, 10 mL−1) and 1.5 mL of Triton 185 
X-100 1% (v/v)] were added to each well, along with 30 μL of the parasite homogenate 186 
fraction, 10 μL of riboflavin (0.44 mg, 10 mL−l), and an equivalent volume of the 187 
different concentrations of the compounds being tested. Seven different concentrations 188 
were used for each agent, from 0.1 to 100 μM. In the control experiment, the volume 189 
was made up to 1000 μL with 50 mM potassium phosphate buffer (pH 7.8, 3 mL), and 190 
30 μL of the parasite homogenate fraction were added to the mixtures containing the 191 
compounds. Next, the absorbance (A0) was measured at 560 nm in a UV 192 
spectrophotometer. Afterward, each well was illuminated with UV light for 10 min 193 
under constant stirring and the absorbance (A1) was measured again. The human CuZn-194 
SOD and substrates used in these assays were obtained from Sigma-Aldrich®. The 195 
resulting data were analyzed using the Newman-Keuls test. 196 
RESULTS 197 
In vitro antileishmanial evaluation 198 
In a first step we assayed the in vitro antileishmanial activity of compounds 1–20 on 199 
both extra- and intracellular forms of the parasites. Table 1 shows the IC50 values 200 
obtained after 72 h of exposure when compounds 1–20 were tested on extra- and 201 
intracellular forms of L. infantum, L. braziliensis and L. donovani. Toxicity values 202 
against J774.2 macrophage after 72 h of culture were also calculated and Selectivity 203 
Index (SI) values for the amastigote form have also been included in Table 1. Results 204 
obtained for the reference drug glucantime were included in all cases for comparison. 205 
An overall analysis of the biological data evidenced that nine of the screened 206 
compounds (3, 4, 7, 11, 12, 14, 17, 18 and 19) showed high activity against at least one 207 
of three Leishmania species in both promastigote and amastigote forms. For example, 208 
the SI of compound 3 exceeded that of the reference drug in L. infantum by 150-fold, by 209 
2337-fold in L. braziliensis and by 1215-fold in L. donovani. Different authors have 210 
claimed that compounds having SI values greater than 20 can be considered ideal 211 
candidates for further development as leishmanicidal drugs (Nwaka and Hudson, 2006). 212 
This requirement is satisfied by compounds 3, 4, 6, 7, 10 and 17 (17 only in L. 213 
donovani).  214 
Table 1 215 
Infectivity assay  216 
In order to gain a better insight into the activities of the lead compounds 3, 4, 6, 7, 10 217 
and 17, their effect on the infectivity and intracellular replication of amastigotes was 218 
subsequently determined. Macrophage cells were grown and infected with 219 
promastigotes in the stationary phase. The parasites invaded the cells and underwent 220 
morphological conversion to amastigotes within 1 day after infection. On day 10, the 221 
rate of host cell infection reached its maximum (control experiment). We used the IC25 222 
of each product as the test dosage. Figure 1 shows the effect of the studied derivatives 223 
on the infection and growth rates of the three Leishmania species. A measure of the 224 
average number of amastigotes per infected macrophage led to similar conclusions: in 225 
the case of L. infantum (Figure 1A), all compounds were more effective than 226 
glucantime. Amastigote numbers obtained on L. braziliensis (Figure 1B) also showed 227 
that all compounds were clearly more effective than glucantime under the tested 228 
conditions. It was also observed that the infection rate decreased with respect to the 229 
control and, furthermore, the six compounds (3, 4, 6, 7, 10 and 17), were also 230 
remarkably more effective in decreasing parasite infectivity than glucantime at a IC25 231 
dose. 232 
Figure 1 233 
Metabolite excretion 234 
Trypanosomatids are unable to completely degrade glucose to CO2 so that they excrete 235 
part of the hexose skeleton into the medium as partially oxidized fragments. The nature 236 
and percentage of the oxidized fragments depend on the pathway used for glucose 237 
metabolism (Turrens, 2004). The catabolism products in Leishmania species are 238 
principally succinate, acetate, D-lactate and L-alanine (Kirkinezos and Moraes, 2001). 239 
In order to acquire information regarding the effects of 3, 4, 6, 7, 10 and 17 on the 240 
glucose metabolism of the parasite, we obtained the 1H NMR spectrum of three species 241 
of Leishmania (L. infantum, L. braziliensis and L. donovani) promastigotes treated with 242 
the test compounds (compound 17 only in L. donovani); the final excretion products 243 
were qualitatively and quantitatively identified. Figure 2 shows the results obtained and 244 
the comparison with those found for untreated control promastigotes. 245 
All the compounds induce an increase in succinate production in the three species of 246 
Leishmania ranging from 16.1 to 251.3% (Compound 17 only in L. donovani) as can be 247 
observed in Figure 2. This effect is observed in L. donovani to a lesser extent (Figure 2 248 
C) except for compound 10 that presents a higher accumulation of succinate in L. 249 
donovani than in L. infantum and L. braziliensis. 250 
SOD enzymatic inhibition in the Leishmania parasites and in human erythrocytes 251 
Considering the obtained results, we decided to test the effects of these compounds on 252 
Fe-SOD isolated from L. infantum, L. braziliensis and L. donovani over a range of 253 
concentrations, from 0.1 to 100 µM. We used promastigote forms of both species, 254 
which excrete Fe-SOD when cultured in a medium lacking inactive FBS ((Kirkinezos 255 
and Moraes, 2001). The inhibition data obtained are shown in Figures 3 (A, B and C), 256 
and the corresponding IC50 values are included for easier evaluation of the displayed 257 
graphs; for comparison, Figure 3A shows the effects of the same compounds on CuZn-258 
SOD obtained from human erythrocytes.  259 
Regarding the SOD enzymatic inhibition in the Leishmania parasites and in human 260 
erythrocytes (Figure 3), the most remarkable result was the inhibitory effect on Fe-SOD 261 
found for the highly antileishmanial compounds 3, 4 and 7 in the three species tested, 262 
whereas their inhibition of human CuZn-SOD was clearly lower. If we consider the IC50 263 
calculated for L. infantum, inhibition of Fe-SOD by compounds 3, 4 and 7 was 25- , 11- 264 
and 29-fold higher, respectively, than inhibition of CuZn-SOD. Compound 3 showed a 265 
Fe-SOD inhibition 25-, 66- and 10- times higher than CuZn-SOD inhibition in L. 266 
infantum, L. braziliensis and L. donovani, and compound 7 showed the respective 267 
values of 29-, 14- and 36. Therefore, compounds 3 and 7 could be considered the most 268 
selective inhibitors of Fe-SOD. 269 
Figure 2 270 
Figure 3 271 
DISCUSSION 272 
As explained above (Moreno-Viguri et al 2016), previous studies have indicated that 273 
arylaminoketone Mannich base-type compounds may be considered prospective 274 
chemotherapeutic drugs in the treatment of Chagas disease caused by T. cruzi parasites 275 
(Turrens, 2004). We now comment on the results obtained regarding the antiparasitic 276 
activity of compounds 1–20 (Table 1) against three significant species of Leishmania: 277 
L. infantum, L. braziliensis and L. donovani. It was shown that the inhibition activities 278 
against intracellular forms of the parasites of studied compounds (17 with efficacy only 279 
against L. donovani) were higher than those found for the reference drug glucantime, 280 
whereas the effect on extracellular forms was more random. Regarding the toxicity in 281 
mammalian cells, the tested compounds were found to be much less toxic for 282 
macrophages than the reference drug. Therefore, compounds 3, 4, 6, 7, 10 and 17 were 283 
considered the lead ones due to their excellent antileishmanial activity and were selected 284 
for subsequent studies.  285 
Interestingly, the best SI results for the more representative intracellular forms were 286 
obtained in L. infantum and L. donovani, two species forming part of the L. donovani 287 
complex, pointing towards a greater specificity towards parasites causing the 288 
particularly harmful visceral leishmaniasis in both its European and American versions.  289 
With regard to the structure-activity relationship, in general, derivatives with the 290 
benzo[b]thiophene scaffold are less cytotoxic than the rest of the derivatives.  291 
In the infectivity assay (Figure 1) all the compounds were more effective in relation to 292 
IC25 than glucantime. The infection rates decreased with respect to the control and the 293 
reference drug glucantime. The measure of the average number of amastigotes per 294 
infected macrophage led to similar conclusions. All these data seem to be in line with 295 
results previously described for T. cruzi (Moreno-Viguri et al. 2016). 296 
Regarding the studies to elucidate the possible mechanism of action, the studied 297 
compounds produce greater glucose metabolism alteration because they increase 298 
succinate excretion (Figure 2). Detection of large amounts of succinate as a major end 299 
product is a usual feature, because it relies on glycosomal redox balance, enabling re-300 
oxidation of the NADH produced in the glycolytic pathways. It is interesting to mention 301 
that the increase in succinate with these compounds indicates catabolic changes that 302 
could be related to mitochondria malfunction, due to the redox-stress produced by 303 
inhibition of the mitochondrion-resident Fe-SOD enzyme (Marín et al. 2011). 304 
In addition, these compounds led to greater levels of Fe-SOD inhibition. All these data 305 
appear to confirm some type of relation between the antileishmanial activity and the Fe-306 
SOD inhibition, coinciding with the results described in previous work (Ginger, 2005). 307 
Fe-SOD inhibition could also, at another level, be related to the catabolic changes 308 
discussed above because a mitochondrial malfunction, originated from the redox stress 309 
produced by inhibition of the mitochondrion-resident Fe-SOD enzyme, (Marin et al., 310 
2011) should result in severe alteration of pyruvate metabolism and consequently, a 311 
decrease in the production of succinate. Because the Fe-SOD present in mitochondria is 312 
an essential part of the antioxidant protective response of the parasite, its inhibition 313 
would be related to a decrease in the rate of survival for the parasite. 314 
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Figure 1. Effect of arylaminoketone derivatives 3, 4, 6, 7 and 10 on the infection and 483 
growth rates and mean numbers of amastigotes  per infected J774.2 macrophage cell (at 484 
IC25 concentration) of L. infantum. (A), L. braziliensis (B) L. donovani (C). Values are 485 
the means of three separate experiments.  486 
All compounds are statistically significant against glucantime at a p-value <0.05, except 487 
compounds labeled as NS. 488 
Figure 2. Variation percentages in the area of the peaks corresponding to excreted 489 
catabolites by L. infantum (A), L. brasilienzis (B) and L. donovani (C) promastigotes in 490 
the presence of compounds 3, 4, 6, 7 ,10 and 17 at their IC25 compared to a control 491 
sample after 96 h of incubation. 492 
Figure 3. (A) In vitro inhibition of CuZn-SOD in human erythrocytes by compounds 3, 493 
4, 6, 7, 10 and 17. (B–D) In vitro inhibition (%) of Fe-SOD of L. infantum (B), L. 494 
braziliensis (C) and L. donovani (D) promastigotes by compounds 3, 4, 6, 7, 10 and 17. 495 
Values are the average of three separate determinations. Differences between the 496 
activities of the control homogenate and those incubated with the tested compounds 497 
were obtained according to the Newman–Keuls test. IC50 was calculated by linear 498 
regression analysis. 499 
